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Clinical Use of Melatonin in the 
Treatment of Sleep Disorders
Alexander Zakharov and Elena Khivintseva
Abstract
Sleep disorders are a group of conditions that affect the circadian rhythm of 
sleep-wake, leading to social and professional maladaptation. At the moment, there 
is a wide range of medications aimed at the treatment of sleep disorders, but the 
results from their use are not always satisfactory. Benzodiazepines, antidepres-
sants, and antihistamines may cause dependence or withdrawal effects. Melatonin 
(N-acetyl-5-methoxytryptamine) is an endogenous hormone produced by the 
pineal gland that affects intraday, seasonal rhythm, and the sleep-wake cycle. 
Studies of the effects of melatonin have demonstrated its ability to synchronize 
circadian rhythms, reduce the latency of slow sleep, increase the duration of sleep, 
and improve its subjective quality. This review highlights the current therapeutic 
possibilities of using melatonin in various sleep disorders, taking into account the 
mechanisms of its action. Also, the prospects of using melatonin due to its chro-
nobiological effect in other sleep disorders, such as parasomnia, sleep-dependent 
respiratory disorders, and hypersomnia, are emphasized. At the moment, mela-
tonin is one of the methods for correcting intraday rhythms and some types of 
insomnia.
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1. Introduction
Sleep is fundamental to the mental and physical health of a person. Lack of 
sleep is a significant risk factor for obesity, diabetes, diseases of the cardiovascular 
 system, as well as anxiety and depressive disorders. Sleep disorders have a sig-
nificant financial burden on the healthcare system and complicate the treatment 
of major somatic diseases. Sleep disorders are a category of diseases that include 
hypersomnia, insomnia (accompanied by difficulty falling asleep, maintaining 
sleep, and early awakening), circadian rhythm disturbance, parasomnia, and sleep-
dependent breathing disorders. The consequence of some sleep disorders is a viola-
tion of falling asleep and maintaining sleep, drowsiness, and, as a consequence, a 
decrease in the quality of life. Some sleep disorders can also lead to severe impaired 
ability to perform every day and professional tasks related to  concentration, 
 switching attention, and spatial perception [1].
The development of pharmacological treatment methods has provoked an 
increase in the frequency of sleep disorders in the last decade, as a result of undesir-
able effects of this therapy. The most common disease is insomnia, which according 
to the classification criteria for mental disorders Diagnostic and Statistical Manual of 
Mental  Disorders IV (DSM-IV) in the general population is found in 4–6%.  
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The main classes of drugs for the treatment of insomnia are barbiturates, benzodi-
azepines, benzodiazepine agonists, antidepressants, and anxiolytics. These drugs 
can cause a large number of side effects associated with excessive daytime sleepi-
ness, decreased concentration, and switching attention and can cause deterioration 
of short-term memory. In some cases, with prolonged use of these drugs, depen-
dence may form, and with cancelation, a “rebound phenomenon” may occur. In this 
regard, it becomes relevant to search for new pharmaceuticals that reduce the num-
ber and severity of these side effects while maintaining the proper level of effective-
ness. One of these drugs, with long-term administration of minimal side effects and 
sufficient effectiveness in certain sleep disorders, is melatonin. Melatonin is mainly 
produced by the pineal gland with a peak of activity at night; the concentration 
fluctuation coincides with the circadian rhythm. Melatonin-based preparations have 
good tolerance in various age periods, without forming dependency [2–4].
Other effects are inherent to melatonin, namely, regulation of circadian, sea-
sonal rhythms; regulation of the psychoemotional and cognitive sphere; antioxi-
dant, neuroprotective, and geroprotective effect; immunomodulatory; vegetative 
stabilizing; and oncological and stress-protective effect.
The multiplicity of effects of melatonin is due to the large number of targets on 
which this hormone has an effect. The most studied mechanism for the implemen-
tation of the action of melatonin remains its effect on suprachiasmal nuclei (SCN) 
of the hypothalamus. Through SCN, the chronobiological effect of melatonin is 
realized and, of course, its hypnotic effects. Melatonin interacts with two types of 
G-protein-bound receptors—MT1 and MT2 [5]. MT1-type receptors are distributed 
in the hippocampus, caudate nucleus, pillow, suprachiasmatic nuclei, paraven-
tricular nucleus, supraoptic nucleus, Meynert nucleus, adjacent nucleus, substantia 
nigra, mammary bodies, and retina. MT2-type receptors are mainly detected in 
the hippocampus, SCN, and the retina. Both types of receptors are expressed by 
neurons and glial cells of the cerebral and cerebellar cortex, in the thalamus, and 
pineal gland [5, 6].
Melatonin is released into the blood plasma as a rhythmic oscillatory pattern, 
which is regulated by SCN neurons. Daylight suppresses the release of melatonin 
through the retinohypothalamic tract, projecting from melanopsin-expressing 
retinal ganglion cells to SCN neurons. It is known, for example, that night illumina-
tion is 2000–2500 Lux within 2 hours, which completely inhibits the secretion of 
melatonin. On the other hand, traditional home light (50–300 Lux) practically 
does not have a suppressive effect on the secretion of melatonin [7]. The neural 
relationship between the structures of the central nervous system, where axons of 
melanopsin-expressing ganglion cells are projected, primarily with SCN neurons 
and the sympathetic nervous system, is via the superior cervical sympathetic gan-
glion, from where the nerve fibers go directly to the pinealocytes and regulate the 
exocytosis of norepinephrine, which activates melatonin synthesis and its release 
[8]. As mentioned above, melatonin easily penetrates through biological barrier: 
it is secreted continuously into the blood plasma and enters various fluids (saliva, 
urine, cerebrospinal fluid, preovulatory follicle, spermatozoa, amniotic fluid, and 
human milk). The maximum level of melatonin in blood plasma is at 03.00–04.00 
at night. The indicator varies depending on the chronotype and is not determined 
in the daytime. Melatonin levels have a pronounced intersubject heterogeneity 
but are steadily repeated in the same person. After birth, the rhythmic production 
of melatonin during the day reaches very high levels by 3–6 years of life and then 
decreases by almost 80% to levels in an adult. The melatonin rhythm is generated 
by the endogenous clock of the hypothalamic SCN neurons, which are affected by 
the light/dark cycle (zeitgeber). Seasonal effects on the secretion of melatonin are 
manifested in an increase in nighttime secretion of melatonin, which is associated 
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with a decrease in plasma of ovarian steroids. On the other hand, urban lighting 
reduces seasonal differences in the secretion of melatonin, cortisol, and thyro-
tropin. Winter-type seasonal affective disorders are characterized by recurrent 
depressive episodes during a short photoperiod.
Melatonin, due to its amphotericity (amphiphilicity), is able to penetrate into 
the cell, organelles, and nuclear membranes and directly interacts with intracellular 
molecules, exerting a non–receptor-mediated effect. Along with this, melatonin 
exerts a receptor-mediated effect on target cells, as a result of the interaction of the 
hormone with either membrane or nuclear receptors [9]. The main physiological 
functions of melatonin are due to its hormonal properties; however, the hormone 
also has an autocrine and paracrine effect, in particular in the retina and gastroin-
testinal tract [10].
Outside of SCN, MT1 and MT2 receptors are also found in large numbers in the 
duodenum, colon, cecum and appendix, gallbladder epithelium, parotid gland, 
pancreas, β-cells of the endocrine system, pancreas, coronary, and cerebral arter-
ies adipose tissue. In addition to membrane receptors for melatonin, there are also 
nuclear receptors: RORα and RORβ. The prevalence of RORα is highest in T and B 
lymphocytes, neutrophils, and monocytes, whereas RORβ are found mainly in the 
brain, pineal gland, retina, and spleen.
The modulating effect on sleep architecture is also realized by melatonin due to 
membrane receptors MT1 and MT2. The activation of the MT2 receptor contributes 
to increasing the duration of slow-wave sleep. The activation of the MT 1 receptor 
has a decrease in the duration of slow-wave sleep [11, 12].
The effects of melatonin, in addition to effects on SCN, on neural networks of 
passive brain function default mode network (DMN) were also demonstrated. Their 
activation is accompanied by the appearance of a feeling of fatigue and is character-
ized by changes typical of sleep in such parts of the cortex as the precuneus located 
in the rostromedial aspect of the occipital cortex [13, 14]. Because the general effect 
of melatonin through two membrane receptors does not increase the duration of 
slow-wave sleep (SWS) [15], the main effect of melatonin is not associated with its 
homeostatic effect on sleep. Therefore, its effect can be attributed to sleep regula-
tion through the circadian component [16].
The multiple representation of melatonin receptors in the central nervous 
system, its effect on one of the key components of the regulation of the sleep-wake 
cycle, leads to the multiplicity of the clinical use of this hormone, especially in 
pathological conditions accompanied by primary or secondary circadian rhythm 
disturbances.
2. Melatonin and sleep disorders
2.1 Melatonin and disorders of the sleep-wake cycle
Circadian disturbances of the sleep-wake rhythm are associated with disconnec-
tion of the synchronization of the endogenous circadian rhythm and environmental 
influences. Melatonin signals the onset of darkness, and activation of its production 
indirectly depends on the activity of intrinsically photosensitive retinal ganglion 
cells (ipRGC) or true light-sensitive retinal ganglion cells. However, there is also 
an endogenous melatonin release profile that allows SCN activation regardless of 
external light, maintaining sleep-wake rhythms and neuroendocrine rhythms in 
a 24-hour cycle. However, the absence of external-stabilizing effect of zeitgeber 
(daily light change) can lead to the formation of a non-24-hour sleep-wake cycle. 
For example, in completely blind subjects, it is quite common (in 50–75% of cases) 
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to observe a non-24-hour sleep-wake disorder (non-24-hour sleep-wake disorder), 
the occurrence of which is associated with the inability to synchronize with changes 
in light [17]. Circadian rhythm disorders can be divided into conditions that may 
be caused by endogenous or exogenous factors. The first subgroup includes the 
syndrome of delayed onset of sleep and wake phases (advanced sleep-wake phase 
disorder), early onset of the sleep phase (delayed sleep-wake phase disorder), 
irregular sleep-wake rhythm disorder (irregular sleep-wake rhythm disorder), 
and non-24-hour sleep-wake cycle (non-24-hour sleep-wake disorder). The group 
with exogenous causes of occurrence includes jet lag disorder, a disorder caused 
by a shift work schedule (shift work disorder) or a result of behavioral features 
of going to bed and violation of the work and rest regime in the format of about 
24-hour circadian rhythm. The circadian rhythm is regulated by melatonin, while 
the production of melatonin itself is regulated by external influences, the most 
important of which is the effect of light, which activates the retinal ganglion cells 
containing the light-sensitive pigment melanopsin. External influences with exces-
sive activation of signal systems implemented through SCN excitation are caused by 
the lifestyle of modern people, the use of electronic devices. Such excessive activa-
tion can lead to difficulty in initiating sleep, reducing its duration [18]. A decrease 
in melatonin secretion serves as one of the main mechanisms for the occurrence of 
such a disorder as delayed sleep phases [19]. There is a positive modulating effect of 
melatonin on the circadian rhythm of sleep-wakefulness and sleep efficiency both 
in pathology and in healthy subjects [20].
In separate studies in patients with delayed onset of sleep and wake phases in 
combination with attention deficit hyperactivity disorder, therapy was performed 
at a dose of 10 mg, lasting for 4 or more years. The therapeutic effect of melatonin 
was shown in reducing the start time of sleep and increasing the time of wakeful-
ness in these patients. The use of melatonin in a dose of 3 mg for the treatment of 
disorders of the sleep-wake cycle in children did not show any effects on the process 
of puberty in the long-term period. However, it should be noted that these studies 
are isolated and do not carry a sufficiently high level of evidence [21]. However, 
even this long-term use of melatonin was not accompanied by any significant or 
serious adverse events.
Table 1 presents data on the efficacy of melatonin and its agonists in various 
forms of sleep-wake disorder [21].
According to the recommendations for the treatment of these conditions, 
melatonin and its agonists have a sufficient level of evidence when applied to the 
diagnosis of delayed onset of sleep and wake phases and irregular sleep-wake 
Type of disorder 
(syndrome)
Efficiency Level of 
evidence
Delayed onset of the phases 
of sleep and wakefulness
Recommended for adults with or without depression
Recommended for children and adolescents without or 
with concomitant psychiatric pathology
Low
Recommended for children and adolescents without or 
with concomitant psychiatric pathology
Moderate
Non-24-hour sleep-wake 
cycle
Recommended for blind adults Low
Irregular rhythm of 
sleep-wakefulness
Not recommended for seniors with dementia. 
Recommended for children and adolescents with 
neurological pathology
Moderate
Table 1. 
The use of melatonin and its agonists in various types of disorders of the sleep-wake cycle.
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rhythm syndrome. Concerning the recommendations on the dose of melatonin, no 
consensus has been formed, since in studies on the basis of which recommenda-
tions are formed with the use of a wide variety of doses of melatonin, from 0.3 
to 10 mg. For the non-24-hour sleep-wake cycle syndrome alone, in 2014, the US 
Food and Drug Administration (FDA) approved a melatonin agonist (tasimelteon) 
as a therapy.
However, individual studies have demonstrated a high therapeutic effect in the 
treatment of completely blind patients with N24HSWD immediate-release melato-
nin preparations. Taking a 0.5–10 mg of melatonin helped accelerate the synchro-
nization of the endogenous sleep-wake rhythm with a 24-hour rhythm, according 
to the profile of the production of melatonin and cortisol. Also, separate studies 
demonstrate that drugs with modified melatonin release can also be effective in 
stabilizing circadian rhythms in completely blind patients with N24HSWD [22].
The so-called sleep-wake cycle disturbance states, namely, “jetlag,” which 
occurs when changing time zones during an eastbound flight, can be corrected 
quite well with exogenous melatonin. In separate studies, various doses of mela-
tonin (from 0.5 to 10 mg) used at bedtime, 3 days before the transmeridian flight 
and 5 days after it, were used to treat jetlag [23, 24]. The effectiveness of melatonin 
in most studies was already shown during the first 3 days after the completed 
flight, but subsequently, patients who did not take melatonin showed the same 
sleep-wake cycle characteristics as the group of people taking it. The main effect 
of melatonin in the first 3 days after the transmeridian flight was an increase in 
the duration and quality of night sleep, based both on subjective sensations and on 
the data of objective methods for recording sleep patterns (polysomnography and 
actigraphy) [25, 26].
At the same time, melatonin had a positive effect on latency and duration 
of sleep. Melatonin agonists have also shown their effectiveness in accelerating 
adaptation to a new time zone. Melatonin agonists (ramelteon and tasimelteon) 
are approved by the FDA for the treatment of time zone change syndrome (“jet 
lag”). As a pharmacological method of treating these types of disorders, the use 
of agomelatine, long-acting melatonin, and tasimelteon was approved by the 
European Medicines Agency. Most studies have evaluated the effects of melato-
nin on jet lag when changing time zones eastward, but there are also few studies 
showing its effectiveness in treating jet lag with a transmeridian flight (12 time 
zones) westward [27, 28]. A definitive statement regarding the most effective dose 
of melatonin in jet lag treatment cannot be made; however, separate studies have 
shown a greater efficacy of a 5 mg immediate-release melatonin dose relative to the 
group of patients taking 2 mg delayed-release melatonin [24].
Melatonin, as a dietary supplement, is used widely enough but is not an 
approved treatment for these types of disorders. The reason for this, as a rule, is the 
lack of sufficient evidence in the form of clinical trials conducted at the appropriate 
level to evaluate the clinical effects.
2.2 Melatonin in the treatment of insomnia
Insomnia is a pathological condition caused by a variety of endogenous and 
exogenous factors. Insomnia is characterized primarily by the difficulty of initiating 
and maintaining sleep, which results in low-quality daily activity. People suffering 
from chronic insomnia are usually more prone to psychiatric disorders, primarily 
anxiety-depressive disorders, and cardiovascular diseases [29]. With age, the preva-
lence of insomnia increases; one of the reasons for this is an involutional decrease 
in the level of secretion of melatonin [30], a decrease in its concentration with SCN 
[6]. According to epidemiological studies, 6% of adults in industrialized countries 
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suffer from a chronic form of insomnia [30]. In addition to night manifestations, 
accompanied by an increase in sleep latency, a decrease in sleep time, low sleep effi-
ciency, and an increase in wakefulness during sleep, daytime manifestations of this 
disease are also formed, namely, fatigue, decreased short-term memory, decreased 
mood, headaches, and gastrointestinal disturbances intestinal tract [31].
The architecture of sleep begins to change already in adulthood, while initially 
a decrease in the duration of slow sleep is observed. The main goals of treating 
insomnia are to improve the quality of sleep and its duration and also to improve 
daily activity. As polysomnographic markers used to objectify the effectiveness of 
therapy insomnia, wake time after sleep onset (WASO), sleep onset latency (SOL), 
the number of awakenings, and sleep effectiveness. Despite this, polysomnography 
is an optional research method. Its use is advisable in cases of suspected secondary 
genesis of insomnia, as well as to exclude other sleep disorders.
According to the questionnaire, patients with insomnia have higher values 
(more than 7 points) when questioning on the Insomnia Severity Index (ISI) scale. 
According to the Pittsburgh Sleep Quality Index (PSQI), there may be more than 
5 points. The Beck Depression Questionnaire demonstrates at least the presence 
of minimal signs of a depressive state, reaching values of 10 or more points. To 
assess the long-term effects of therapy, keeping a sleep diary is one of the objective 
methods (recommendation level IIB, based on expert consensus).
According to the recommendations of the American Academy of Sleep Medicine 
(AASM) from 2008, the use of benzodiazepines and a melatonin receptor agonist 
(ramelteon) is recommended as a therapy for primary insomnia (psychophysi-
ological, idiopathic, and paradoxical forms). At the same time, there are no clear 
recommendations regarding the order of initiation of therapy with one of the 
groups of these drugs. The simultaneous use of melatonin and benzodiazepines 
is acceptable, to reduce the severity of side effects of the latter. It has been shown 
that agonists of melatonin receptors have a positive effect on the subjective quality 
of night sleep and their positive therapeutic effect is objectively confirmed by a 
polysomnographic study. At the same time, the main criteria for the effectiveness 
of the treatment of insomnia are achieved, namely, a decrease in WASO and SOL by 
at least 30 minutes, a decrease in the frequency of awakenings, an increase in sleep 
duration of more than 6 hours, and an increase in sleep efficiency (ratio of sleep 
time to recording time) to 80% or more [32, 33]. However, given the short half-life 
of melatonin and melatonin receptor agonists (e.g., ramelteon), the main clinical 
effects of these drugs are aimed at the treatment of presomic disorders [33]. In this 
case, immediate-release melatonin has no other effects on the structure of night 
sleep, except as a decrease in sleep latency. At the same time, there are observations 
demonstrating, but not explaining, the reason for the increase in the efficiency of 
activation of MT1 receptors with SCN, which increases their sensitivity to mela-
tonin, which may be the basis of the therapeutic effect in relation to presominal 
disorders [34].
One of the mechanisms for implementing the hypnotic effect of melatonin can 
be realized through hormonal stabilization of the limbic system, which is involved 
in adaptogenic behavior [7, 9].
According to the recommendations of the European Sleep Research Society 
(ESRS) from 2017, based on a meta-analysis of 109 studies with a total number of 
patients 13,969 for the period from 2005 to 2016, melatonin and melatonin recep-
tor agonists have shown unequivocal efficacy in the treatment of insomnia (weak 
recommendation – low-quality evidence). According to the results of individual 
studies, polysomnographic criteria for the effectiveness of insomnia therapy were 
achieved, namely, a decrease in sleep latency and an increase in the total sleep time 
and sleep efficiency [35, 36]. In a number of studies, even a decrease in the number 
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of nocturnal awakenings was noted, which demonstrated effectiveness in relation 
to intrasomnic disorders. According to these studies, no dependence of the clinical 
effect on the dose of melatonin used was revealed. A common opinion formed as a 
result of the analysis of research data is a high safety profile for melatonin.
Melatonin is approved in Europe for the treatment of primary insomnia in adults 
over the age of 55, with a level of evidence of 1B (level of evidence based on the 
results of several randomized, placebo-controlled trials) [37].
Studies are demonstrating the effectiveness and perspective use of new forms 
of melatonin delivery [38]. Modified release tablet formulations with melatonin 
(MLT) are clinically more useful in initiating and maintaining sleep in elderly 
insomniacs than those designed for immediate release. The release of MLT from 
formulation F(nf)2 (nanofiber mats incorporated into 3-layered tablets containing 
lactose monohydrate both in the upper and lower layers) was found to be in closer 
alignment with these effects than the other delivery systems [39].
Among healthy children, sleep problems are observed in 20–40% [40] and, 
among children with impaired development of the nervous system, up to 80%  
[41, 42]. In pediatric practice, sleep disturbance is most often found among children 
with autism spectrum disorder (ASD), attention deficit hyperactivity disorder 
(ADHD), as well as in anxiety or depressive states [43]. Numerous clinical stud-
ies have shown the effectiveness of melatonin in the treatment of falling asleep in 
patients of various age groups, including children with ASD [44] or adolescents 
suffering from depression [45]. The physiological concentration of melatonin is 
crucial for the development of cognitive and behavioral functions [46]. A number 
of studies have demonstrated a causal relationship between a decrease in melatonin 
levels and the onset of ASD. Forty percent of children with ASD experienced an 
increase in serotonin while a decrease in melatonin. An increase in the intermediate 
metabolite of N-acetylserotonin (NAS) was also observed in 47% of patients [47]. 
One of the reasons for a decrease in the level of melatonin and an increase in the 
concentration of its precursor may be due to a violation of the activity of hydroxy-
indole-O-methyltransferase [46].
Despite the lack of clinical recommendations, the use of delayed-release 
melatonin is recommended for children with difficulty maintaining sleep, while 
immediate-release melatonin is recommended for children with difficulty falling 
asleep [41, 48]. According to individual recommendations (level of evidence C), 
melatonin should be used as a sleep inducer at a dose of 1–3 mg 30 minutes before 
bedtime. To obtain chronobiological effects, a melatonin drug should be taken with 
immediate release 3–4 hours before bedtime at a dose of 0.2–0.5 mg; the maximum 
dose for children is 3 mg and for adolescents 5 mg [49].
Despite the fact that in a number of studies melatonin has been shown to be 
effective in treating insomnia in patients with attention ADHD, its effect on cogni-
tive function and behavior in this population of children has not been found [50].
Melatonin has also been shown to be effective in patients with secondary iatro-
genic insomnia receiving beta blockers for hypertension [51] as well as in children 
with attention deficit hyperactivity disorder (level of IA recommendations based on 
the results of randomized, placebo-controlled clinical trials) [52, 53].
The use of melatonin in pediatric practice is associated with a minimal number 
of side effects. However, there are reports of undesirable phenomena of mild sever-
ity, namely, an increase in the clinical manifestations of nocturnal enuresis, morn-
ing drowsiness, and extremely rare insomnia [54].
Thus, according to the main clinical recommendations in the treatment of 
insomnia, melatonin has a positive effect both on the subjective quality of night 
sleep and on its objective characteristics. The drug has a high level of evidence 
of its effectiveness in the long-term therapy of insomnia in patients older than 
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55 years, associated mainly with the difficulty of falling asleep and the poor quality 
of night sleep. Ensuring physiological control of the sleep-wake cycle in children 
with pathology of the development of the nervous system and patients older than 
55 years with insomnia is the goal of replacement therapy with melatonin, since in 
both groups there is a decrease in the secretion of endogenous melatonin during the 
night [55, 56].
2.3 Melatonin and parasomnia
Parasomnias are undesirable physical or psychological phenomena that usu-
ally form at certain stages of sleep, causing a number of clinical manifestations, 
including the formation of secondary insomnia. Quite often, parasomnia, especially 
accompanied by motor manifestations, can lead to injuries of varying severity and 
the formation of psychological problems or social maladaptation [21, 57]. The most 
striking in its clinical manifestation is REM behavior disorder (RBD). In the treat-
ment of this form of parasomnia, clonazepam is most successfully used. But, the 
use of this drug is associated with numerous side effects typical of benzodiazepines, 
especially if the elderly patient has sleep-related breathing disorders (SRBD). An 
alternative pharmacological method is the use of melatonin. Melatonin also causes 
a decrease in the frequency and severity of motor activity during an RBD episode, 
which leads to a decrease in the frequency and severity of injuries. According to the 
results of a few studies, the use of melatonin at a dose of 3–15 mg led to a signifi-
cant reduction in paradoxical sleep without atony, as well as the severity of motor 
manifestations of behavior disorder in the REM phase [58]. One of the options for 
therapeutic treatment may be taking the drug melatonin for 5–7 days at a minimum 
dose of 3 mg, followed by an increase in the dose of the drug every 5–7 days to a 
maximum of 12 mg at night [59, 60]. Little information is available regarding the 
efficacy of prolonged forms of melatonin or agonists in patients with RBD. There 
were also no comparisons of the clinical efficacy of clonazepam and melatonin.
Indeed, a number of studies demonstrate a more effective therapeutic effect 
with the combination of clonazepam and melatonin [61]. The potentiation of the 
effects of melatonin and clonazepam in the context of RBD therapy has no defini-
tive explanation. It is believed that clonazepam reduces the phase activity inherent 
in paradoxical sleep, but at the same time, motor activity and minimal disturbance 
of behavior may remain, according to a polysomnographic survey [62]. The effect 
of melatonin in combination with clonazepam is due to the modulating effect of the 
structure of paradoxical sleep, reducing the number of transitions to other stages 
[59]. An alternative hypothesis explaining the effectiveness of melatonin in RBD 
may be its effect on increasing the effect of GABA on the GABA receptors of motor 
neurons of the anterior horns of the spinal cord, which leads to more intense muscle 
atony. Efficiency may also be related to the fact that melatonin helps to reduce the 
concentration of calmodulin, which affects the structure of the cytoskeleton and 
nicotinic acetylcholine receptors of skeletal muscles, which also leads to a progres-
sive decrease in muscle tone [61]. The presence of a favorable safety profile makes 
the use of melatonin more attractive relative to clonazepam, especially in the 
elderly [61]. Therefore, in some few clinical trials, melatonin is used as a first-line 
therapy for RBD, especially in the presence of cognitive impairment, Parkinsonism, 
or SRBD. In the presence of minimal effectiveness of melatonin or a decrease in 
its effectiveness during therapy, clonazepam should be additionally prescribed. 
According to AASM recommendations, melatonin has a “B” level of evidence 
regarding its effectiveness. Doses of the drug in the studies on the basis of which 
these recommendations were made ranged from 8 to 12 mg; therefore, there are no 
clear recommendations regarding the dose of administration [63].
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There is also another class of parasomnia in the treatment of which the effec-
tiveness of melatonin was studied. These are parasomnia associated with slow eye 
movement, which is defined as undesirable motor and psychophysiological mani-
festations that occur at the time of awakening from a slow-wave sleep. Parasomnia 
associated with slow eye movement is defined as undesirable motor and psycho-
physiological manifestations that occur at the time of awakening from a slow-wave 
sleep [64]. In cases of severe clinical manifestations of these forms of parasomnia, 
benzodiazepines (clonazepam) or antidepressants (imipramine or clomipramine) 
may be used. When walking in a dream, the drugs of choice are benzodiazepines or 
selective serotonin reuptake inhibitors (SSRIs), such as paroxetine and imipramine 
[64]. The use of melatonin did not reveal a reliable therapeutic effect on the clinical 
manifestations of these forms of parasomnia. There are only a few studies on the 
use of melatonin as a first-line therapy for nightly fears in children; the first-line 
drug is melatonin or L-5-hydroxytryptophan [65]. The absence of a significant 
clinical effect is associated with the absence of a homeostatic effect on sleep in 
melatonin.
2.4  Melatonin in the treatment of complications of sleep-dependent  
respiratory disorders
Sleep-dependent respiratory disorders are represented by several types of 
pathological conditions: Obstructive sleep apnea (OSA), central sleep apnea, 
sleep-related hypoventilation, and sleep-related hypoxemia disorder. Most studies 
are devoted to the study of melatonin metabolism in OSA. A number of studies have 
demonstrated impaired melatonin secretion in OSA. At the same time, it is believed 
that the decrease in secretion is secondary. There is also data on the relationship 
between the concentration of melatonin at night and the duration of night sleep, as 
well as body weight [66–68]. Some studies have shown a relationship between the 
severity of OSA and the degree of decrease in melatonin [69]. Approximately 25% 
of patients with OSA have an altered circadian rhythm of melatonin secretion. In 
patients with OSA with a maintained rhythm of secretion, peak melatonin levels at 
night are significantly lower than in healthy people. The 3-month treatment period 
with continuous positive airway pressure (CPAP) can help restore the physiological 
rhythm of melatonin in patients with OSA with an impaired secretion profile [70]. 
One of the uses of melatonin is its use as a drug that reduces the complications asso-
ciated with respiratory failure during sleep. Numerous studies on biological models 
demonstrate the positive effect of melatonin on the unfolding pathophysiological 
cascade of changes in the body in the presence of sleep-dependent respiratory dis-
orders. For example, melatonin inhibits an increase in glucose, the concentration of 
which increases during periods of apnea [71]. Melatonin modulation of the activity 
of adenosine monophosphate-activated protein kinase reduces the progression of 
cardiac muscle hypertrophy. Melatonin also inhibits the expression of inflammatory 
cytokines, such as tumor necrosis factor alpha, interleukin-6, and cyclooxygenase-2 
[72]. It also helps to reduce the severity of Ca2+ caused by impaired myocardial 
contractile function, thus reducing the manifestations of endothelial dysfunction.
The use of melatonin as a prophylactic helps to prevent cardiac remodeling due 
to hypoxia arising from obstructive apnea [73]. Effects on the cardiovascular system 
are also realized due to the ability of melatonin and melatonin receptor agonists to 
inhibit bradykinin B2 receptors, as well as dimerization of angiotensin-converting 
enzyme I, improving therapeutic control of blood pressure [74]. Another way of 
realizing the effects of melatonin is the stabilizing effect on angiotensin II receptors 
and ACE-B2R dimers, which increases the production of nitric oxide by endothelial 
cells, increasing tissue perfusion. The activation of the MT1 receptor promotes 
Melatonin - The Hormone of Darkness and Its Therapeutic Potential and Perspectives
10
vasoconstriction and MT2 receptor vasodilation. Thus, melatonin can act as a thera-
peutic agent in the treatment of cardiovascular diseases and hypertension resulting 
from comorbid diseases in sleep-dependent respiratory disorders. These effects of 
melatonin in carotid-dependent respiratory disorders were found as a result of a few 
studies; therefore, they do not have a sufficient recommended level.
2.5 Melatonin in the treatment of hypersomnia
Hypersomnia, such as type I and type II narcolepsy, and idiopathic hypersom-
nia, are diseases of which the main clinical syndrome is excessive daytime sleepi-
ness. At the same time, drowsiness, being one of the obligate syndromes of diseases, 
can be modulated by sleep disturbances, observed in these patients, associated 
with disturbances in sleep structure, and the stability of being in a slow-wave 
sleep. Currently, drugs approved by FDA, for example, include methylphenidate, 
modafinil, oxybate, and pitolisant. Methylphenidate, being an analogue of amphet-
amine, blocks the transport of dopamine and norepinephrine, increasing their con-
centration. This drug has a fairly large number of side effects. Modaphenyl is better 
tolerated but may cause psychological dependence on administration [75]. Oxybate 
and pitolisant are well tolerated. Pitolisant is currently undergoing an expansion of 
indications up to 6 years of age in the treatment of types 1 and 2 narcolepsy.
Melatonin can affect the severity of hypersomnia in these patients indirectly due 
to the effect on the architecture of night sleep. A positive impact on the architecture 
of night sleep is realized by increasing the representation of paradoxical sleep. 
The positive effects of melatonin administration in patients with hypersomnia in 
Parkinson’s disease have been described, slowing down the decrease in the loss of 
dopamine-producing neurons and contributing to the suppression of dopamine 
transport [76]. Presumably, one of the causes of excessive daytime sleepiness in 
Parkinson’s disease is the decrease in the concentration of melatonin [77]. The use 
of melatonin in patients with neurodegenerative diseases is promising, since a num-
ber of interesting effects of melatonin exposure were obtained on biological models. 
For example, melatonin, freely penetrating the blood-brain barrier, activates 
brain-derived neurotrophic factor and cyclooxygenase-10, suppressing plasma 
tumor necrosis factor (TNF-alpha) and IL-10 levels. In experiments, a decrease in 
the number of apoptotic cells induced by phenylhydrazine was demonstrated. These 
studies confirm the role of melatonin in neuroprotection and protection against 
apoptosis in oxidative damage to neurons [78]. According to domestic guidelines 
for the treatment of nonmotor manifestations of Parkinson’s disease, melatonin is 
recommended for use as a therapy for excessive daytime sleepiness [79].
3. Conclusion
A decrease in the secretion of melatonin is often observed with aging and 
diseases of various etiologies. Inadequate sleep hygiene, namely, excessive night 
illumination or night work, are the most common causes of suppression of pineal 
melatonin production, which has a chronobiological effect on the body. A decrease 
in the production of melatonin in some cases can be caused by neurodegeneration, 
accompanied by a change in the functioning of SCN, disrupting the operation of 
the circadic oscillator. The most common manifestations of epiphyseal deficiency 
of this hormone are various functional psychopathological disorders in the form of 
insomnia, anxiety, or depressive disorders. The role of melatonin is currently being 
actively discussed in the treatment of insomnia and the sleep-wake cycle disorder.  
A few clinical studies demonstrate the effects in the treatment of the main 
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manifestations of such forms of sleep disorders as hypersomnia and parasomnia. A 
positive effect is noted in the correction of the pathophysiological cascade arising as 
a result of hypoxia against the background of sleep-dependent respiratory disor-
ders. Thus, the numerous clinical effects of melatonin demonstrate its universal 
modulating effect on physiological processes in the body and some common fea-
tures of the pathogenesis of pathological conditions such as insomnia and circadian 
rhythm disturbances.
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